Has Anton Porsteinsson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $294,547 in general payments to Anton Porsteinsson, MD across 190 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anton Porsteinsson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anton Porsteinsson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anton Porsteinsson, MD

Psychiatry · Rochester, NYNPI 1740225028

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $251,277 of the $294,547 with a category attached, or 85.3%. 18 manufacturers reported payments, led by Biogen at 35.2% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$294,547in general payments, 2019–2025

Across 190 payments — averaging $1550.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$104K
E.r. Squibb & Sons, L.L.C.$42K
Eisai Inc.$34K
Acadia Pharmaceuticals Inc$29K
Novo Nordisk AS$20K
Eli Lilly$17K
plus $49K from 12 others

$7,403,049in research payments, 2019–2025

Across 481 payments — averaging $15,391 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$2.2M
Eisai Inc.$1.9M
Eli Lilly$1.6M
Biogen$1M
Novartis$500K
F. Hoffmann-la Roche AG$52K
plus $87K from 4 others

What the payments were for

Consulting fees$251,27785%
Speaking & faculty fees$8,7883%
Travel & lodging$31,47911%
Food & beverage$3,0041%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	32	$103,769
E.r. Squibb & Sons, L.L.C.	21	$41,953
Eisai Inc.	42	$33,999
Acadia Pharmaceuticals Inc	11	$29,225
Novo Nordisk AS	6	$19,787
Eli Lilly	2	$16,675
Otsuka Pharmaceutical Development & Commercialization, Inc.	7	$10,260
Lundbeck LLC	16	$9,677
Merck	12	$9,499
Grifols Shared Services North America, Inc.	10	$5,019
Novartis	2	$4,400
H. Lundbeck A S	5	$3,144
Corium, LLC	7	$2,786
Avanir Pharmaceuticals, Inc.	11	$2,196
Novo Nordisk	3	$1,403
AbbVie	1	$525
Genentech USA, Inc.	1	$150
F. Hoffmann-la Roche AG	1	$80

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUPLAZID$29,225
REXULTI$22,677
ADUHELM$20,065
Leqembi$4,689
Albutein$3,800
ADLARITY$1,840
Flebogamma DIF$1,151
Azstarys$819

How this compares

$294,547 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Medicare billing

Part B allowed, 2024

$2,792

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Rivastigmine	65	$11,242
Memantine Hcl	209	$6,528
Memantine Hcl ErMemantine Hcl	63	$5,842
Galantamine ErGalantamine Hbr	45	$5,107
Donepezil Hcl	167	$1,342
Escitalopram Oxalate	109	$1,079
RivastigmineRivastigmine Tartrate	14	$628
Aripiprazole	26	$326
Risperidone	38	$249
Quetiapine Fumarate	32	$233
Buspirone Hcl	15	$148
Levetiracetam	12	$140
Olanzapine	14	$124
Gabapentin	12	$83

Paid to pharmacies, not to this prescriber.

Other psychiatry in Rochester

Tulio OrtegaRochester$319K
Leslie CitromePomona$5.7M
Sanjay GuptaCheektowaga$1.9M
Richard PriceMonsey$1.7M
Adam AshtonAmherst$1.6M
Christoph CorrellGlen Oaks$1.5M
Manish ZinzuvadiaNew York$1.3M
George KruseBronx$1.2M
Jianping ChenNew York$1.2M
Horacio CapoteAmherst$1.1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →